Biotech Values

[DewDiligence]

SNY pulls Campath to prevent possible off-label use for MS ahead of regulatory decisions on Lemtrada, which is the same drug at a different dose:

http://www.reuters.com/article/2012/08/20/us-sanofi-drug-idUSBRE87J0KB20120820

The PDUFA date for Lemtrada is 4/12/13. SNY is giving up much by pulling Campath insofar as its worldwide sales in 2011 were only $76M. Campath will still be available to leukemia patients in several countries on a “named-patient” basis.